Affordability Issues of Biotech Drugs in low- and middle-income countries (LMICs)


Affordability Issues of Biotech Drugs in low- and middle-income countries (LMICs)


Abdul Kader Mohiuddin

Department of Pharmacy, World University of Bangladesh,151/8, Green Road, Dhanmondi, Dhaka – 1205, Bangladesh


American Journal of Biotechnology and Bioscience

As indicated by World Bank publication Disease Control Priorities: Improving Health and Reducing Poverty (third edition, 2017), about 20% all out health use universally originated from out-of-pocket payments in 2014. The equivalent was about 40% all out health use for low-income countries, 56% for lower-middle-income countries, and 30% for upper-middle-income countries (WHO, 2016). 33% of the world’s populace needs opportune access to quality-guaranteed medicines while assessments demonstrate that in any event 10% of medicine in low-and middle-income countries (LMICs) are substandard or distorted, costing roughly US$ 31 billion every year (Global Health, 2018). Shockingly, 80% of worldwide cardiovascular passings happen in LMICs which is (halfway) because of the absence of access to healthcare including talented HR, equipped offices and medicines (Global status report on noncommunicable diseases, WHO, 2010). Cost of drugs, antibodies, and diagnostics is a noteworthy weight in LMICs round the globe. Cost of biotech drugs are much higher because of surprising expense caused by the pharmaceutical organizations for clinical preliminary. Biotech drugs have totally changed the administration of a few diseases, including malignant growth and immune system diseases. Albeit essential yet their affordability is as yet a consuming issue, particularly in LMICs.


Keywords: LMICs; out-of-pocket expenditure; cancer treatments; biotech drugs; pharmaceutical patents; biosimilars

Free Full-text PDF


How to cite this article:
Abdul Kader Mohiuddin. Affordability Issues of Biotech Drugs in low- and middle-income countries (LMICs). American Journal of Biotechnology and Bioscience, 2019; 3:13.


References:
1. Beck EJ, Mandalia S, DongmoNguimfack B, Pinheiro E, ‘t Hoen E, Boulet P, Stover J, Gupta A, Juneja S, Habiyambere V, Ghys P, Nunez C. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries? Glob Health Action. 2019;12(1):1586317. doi: 10.1080/16549716.2019.1586317. PubMed PMID: 30983547; PubMed Central PMCID: PMC6484498.
2. Philippidis A. TOP 15 BEST-SELLING DRUGS OF 2018 Sales for most treatments grow year-over-year despite concerns over rising prices. GEN Magazine, March 11, 2019.
3. IQVA. The Global Use of Medicine in 2019 and Outlook to 2023: Forecasts and Areas to Watch. Institute Report, January 29, 2019.
4. Stevens H, Huys I. Innovative Approaches to Increase Access to Medicines in Developing Countries. Front Med (Lausanne). 2017 Dec 7;4:218. doi: 10.3389/fmed.2017.00218. eCollection 2017. Review. PubMed PMID: 29270407; PubMed Central PMCID: PMC5725781.
5. Faruqui N, Martiniuk A, Sharma A, Sharma C, Rathore B, Arora RS, Joshi R. Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India. BMJ Glob Health. 2019 Apr 23;4(2):e001379. doi: 10.1136/bmjgh-2018-001379. eCollection 2019. PubMed PMID: 31139456; PubMed Central PMCID: PMC6509613.
6. Lexchin J. Canada and access to medicines in developing countries: intellectual property rights first. Global Health. 2013 Sep 3;9:42. doi: 10.1186/1744-8603-9-42. PubMed PMID: 24007595; PubMed Central PMCID: PMC3844468.
7. Moon S. Powerful Ideas for Global Access to Medicines. N Engl J Med. 2017 Feb 9;376(6):505-507. doi: 10.1056/NEJMp1613861. Epub 2017 Jan 18. PubMed PMID: 28099819.
8. Prinja S, Bahuguna P, Tripathy JP, Kumar R. Availability of medicines in public sector health facilities of two North Indian States. BMC Pharmacol Toxicol. 2015 Dec 23;16:43. doi: 10.1186/s40360-015-0043-8. PubMed PMID: 26699711; PubMed Central PMCID: PMC4690305.
9. Oberoi SS, Oberoi A. Pharmacoeconomics guidelines: The need of hour for India. Int J Pharm Investig. 2014 Jul;4(3):109-11. doi: 10.4103/2230-973X.138338. Review. PubMed PMID: 25126523; PubMed Central PMCID: PMC4131381.
10. Ewen M, Zweekhorst M, Regeer B, Laing R. Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS One. 2017 Feb 7;12(2):e0171284. doi: 10.1371/journal.pone.0171284. eCollection 2017. PubMed PMID: 28170413; PubMed Central PMCID: PMC5295694.
11. Khuluza F, Haefele-Abah C. The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study. PLoS One. 2019 Feb 12;14(2):e0212125. doi: 10.1371/journal.pone.0212125. eCollection 2019. PubMed PMID: 30753219; PubMed Central PMCID: PMC6372227.
12. Ahmadiani S, Nikfar S. Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective. Daru. 2016 May 4;24(1):13. doi: 10.1186/s40199-016-0151-z. PubMed PMID: 27141958; PubMed Central PMCID: PMC4855755.
13. ‘t Hoen EFM, Kujinga T, Boulet P. Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region. J Pharm Policy Pract. 2018 Dec 4;11:31. doi: 10.1186/s40545-018-0157-7. eCollection 2018. Review. PubMed PMID: 30524732; PubMed Central PMCID: PMC6277991.
14. Scavone C, Sportiello L, Sullo MG, Ferrajolo C, Ruggiero R, Sessa M, Berrino PM, di Mauro G, Berrino L, Rossi F, Rafaniello C, Capuano A; BIO-Cam Group. Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. Front Pharmacol. 2017 Sep 6;8:607. doi: 10.3389/fphar.2017.00607. eCollection 2017. PubMed PMID: 28932193; PubMed Central PMCID: PMC5592230.
15. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006 Sep-Oct;25(5):1319-31. PubMed PMID: 16966729; PubMed Central PMCID: PMC6349207.
16. Vogenberg FR, Young C. Biotech injectable drugs: clinical applications and financial effects. Biotechnol Healthc. 2004 Jul;1(3):31-40. PubMed PMID: 23397364; PubMed Central PMCID: PMC3564314.
17. Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis. 2019 Jan 10;14(1):12. doi: 10.1186/s13023-018-0990-4. PubMed PMID: 30630499; PubMed Central PMCID: PMC6327525.
18. Edelman B. Explaining the cost of biotech therapies. Biotechnol Healthc. 2004 May;1(2):37-41. PubMed PMID: 23372497; PubMed Central PMCID: PMC3555164.
19. Kunnumakkara AB, Bordoloi D, Sailo BL, Roy NK, Thakur KK, Banik K, Shakibaei M, Gupta SC, Aggarwal BB. Cancer drug development: The missing links. Exp Biol Med (Maywood). 2019 May;244(8):663-689. doi: 10.1177/1535370219839163. Epub 2019 Apr 8. PubMed PMID: 30961357; PubMed Central PMCID: PMC6552400.
20. Scavone C, di Mauro G, Mascolo A, Berrino L, Rossi F, Capuano A. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. Front Pharmacol. 2019 Feb 13;10:111. doi: 10.3389/fphar.2019.00111. eCollection 2019. Review. PubMed PMID: 30814951; PubMed Central PMCID: PMC6381027.
21. Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health. 2018 Dec;6(12):e1386-e1396. doi: 10.1016/S2214-109X(18)30346-2. Epub 2018 Oct 18. PubMed PMID: 30342925.
22. Simon R. Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials. Clin Pharmacol Ther. 2017 Dec;102(6):934-941. doi: 10.1002/cpt.814. Epub 2017 Oct 20. Review. PubMed PMID: 28795401.
23. Tay-Teo K, Ilbawi A, Hill SR. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies. JAMA Netw Open. 2019 Jan 4;2(1):e186875. doi: 10.1001/jamanetworkopen.2018.6875. PubMed PMID: 30644967; PubMed Central PMCID: PMC6324319.
24. Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0. PubMed PMID: 31101066; PubMed Central PMCID: PMC6525438.
25. Salmasi S, Lee KS, Ming LC, Neoh CF, Elrggal ME, Babar ZD, Khan TM, Hadi MA. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region. BMC Cancer. 2017 Dec 28;17(1):903. doi: 10.1186/s12885-017-3888-y. PubMed PMID: 29282008; PubMed Central PMCID: PMC5745925.
26. Chivukula MV, Tisocki K. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment. WHO South East Asia J Public Health. 2018 Sep;7(2):90-98. doi: 10.4103/2224-3151.239420. PubMed PMID: 30136667.
27. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O’Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018 Sep-Dec;6(3-4):79-100. doi: 10.1142/S2339547818300020. Epub 2019 Jan 11. PubMed PMID: 30713991; PubMed Central PMCID: PMC6352312.
28. Moreno SG, Epstein D. The price of innovation – the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. J Mark Access Health Policy. 2019 Mar 20;7(1):1583536. doi: 10.1080/20016689.2019.1583536. eCollection 2019. PubMed PMID: 30956782; PubMed Central PMCID: PMC6442120.
29. Ba-Nguz A, Shah A, Bresee JS, Lafond KE, Cavallaro K, Shefer A, Donadel M, Seward JF. Supporting national immunization technical advisory groups (NITAGs) in resource-constrained settings. New strategies and lessons learned from the Task Force for Global Health’s Partnership for influenza vaccine introduction. Vaccine. 2019 Jun 19;37(28):3646-3653. doi: 10.1016/j.vaccine.2019.05.046. Epub 2019 May 23. PubMed PMID: 31130258.
30. Owoeye O, Owoeye O. Biologics and Public Health: Prospects and Challenges. JLaw Med. 2018 Oct;26(1):170-187. PubMed PMID: 30302980.
31. Wilking N, Lopes G, Meier KSS, et al. Can we continue to afford cancer treatment? Eur Oncol Hematol. 2017;13(2):114–119. doi: 10.17925/EOH.2017.13.02.114.
32. Barrios CH, Reinert T, Werutsky G. Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. Ecancermedicalscience. 2019 Jan 22;13:898. doi: 10.3332/ecancer.2019.898. eCollection 2019. Review. PubMed PMID: 30792815; PubMed Central PMCID: PMC6372298.
33. Paudel S, Owen AJ, Owusu-Addo E, Smith BJ. Physical activity participation and the risk of chronic diseases among South Asian adults: a systematic review and meta-analysis. Sci Rep. 2019 Jul 5;9(1):9771. doi: 10.1038/s41598-019-46154-3. PubMed PMID: 31278314.
34. Rijal A, Adhikari TB, Khan JAM, Berg-Beckhoff G. The economic impact of non-communicable diseases among households in South Asia and their coping strategy: A systematic review. PLoS One. 2018 Nov 21;13(11):e0205745. doi: 10.1371/journal.pone.0205745. eCollection 2018. Erratum in: PLoS One. 2019 Jan 25;14(1):e0211588. PubMed PMID: 30462648; PubMed Central PMCID: PMC6248902.
35. Giri M, Giri M, Thapa RJ, Upreti B, Pariyar B. Breast Cancer in Nepal: Current status and future directions. Biomed Rep. 2018 Apr;8(4):325-329. doi: 10.3892/br.2018.1057. Epub 2018 Feb 5. PubMed PMID: 29541453; PubMed Central PMCID: PMC5838313.
36. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8. PubMed PMID: 30620402.
37. Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene BM. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine. 2008 Aug 19;26 Suppl 12:M43-52. doi: 10.1016/j.vaccine.2008.05.005. Review. PubMed PMID: 18945413.
38. India State-Level Disease Burden Initiative Cancer Collaborators. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Oncol. 2018 Oct;19(10):1289-1306. doi: 10.1016/S1470-2045(18)30447-9. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct 3;:. PubMed PMID: 30219626; PubMed Central PMCID: PMC6167407.
39. Gyawali B. Cancer drugs in LMICs: cheap but unaffordable. Oncotarget. 2017 Oct 24;8(52):89425-89426. doi: 10.18632/oncotarget.21976. eCollection 2017 Oct 27. PubMed PMID: 29163757; PubMed Central PMCID: PMC5685678.
40. Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, Stemmer SM, Rosenbaum E. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget. 2017 May 9;8(42):71548-71555. doi: 10.18632/oncotarget.17742. eCollection 2017 Sep 22. PubMed PMID: 29069727; PubMed Central PMCID: PMC5641070.
41. Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, Newcomb P, Hollingworth W, Overstreet K. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013 Jun;32(6):1143-52. doi: 10.1377/hlthaff.2012.1263. Epub 2013 May 15. PubMed PMID: 23676531; PubMed Central PMCID: PMC4240626.
42. Saqib A, Iftikhar S, Sarwar MR. Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan. BMJ Open. 2018 Jun 14;8(6):e019015. doi: 10.1136/bmjopen-2017-019015. PubMed PMID: 29903783; PubMed Central PMCID: PMC6009472.
43. Kolasani BP, Malathi DC, Ponnaluri RR. Variation of Cost among Anti-cancer Drugs Available in Indian Market. J Clin Diagn Res. 2016 Nov;10(11):FC17-FC20. doi: 10.7860/JCDR/2016/22384.8918. Epub 2016 Nov 1. PubMed PMID: 28050395; PubMed Central PMCID: PMC5198348.
44. Gronde TV, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017 Aug 16;12(8):e0182613. doi: 10.1371/journal.pone.0182613. eCollection 2017. Review. PubMed PMID: 28813502; PubMed Central PMCID: PMC5559086.
45. Eniu A, Torode J, Magrini N, Bricalli G; Union for International Cancer Control EML Steering Committee Members. Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines ESMO Open 2016;1:e000030. doi:10.1136/esmoopen-2015-000030.
46. Thomas Z, Saha GK, Gopakumar KM, Ganguly NK. Can India lead the way in neglected diseases innovation? BMJ. 2019 Jan 22;364:k5396. doi: 10.1136/bmj.k5396. PubMed PMID: 30670384; PubMed Central PMCID: PMC6340354.
47. Kalra S, Azad Khan AK, Raza SA, Somasundaram N, Shrestha D, Latif ZA, Bajaj S, Pathan MF, Sahay R, Mahtab H. Biosimilar insulins: Informed choice for South Asia. Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):5-8. doi: 10.4103/2230-8210.164033. PubMed PMID: 26904463; PubMed Central PMCID: PMC4743384.
48. Abdul Kader Mohiuddin (2019) Safety Issues of Biosimilar Products. J Cancer Res Therap Oncol 7: 1-4.
49. Kaduskar PU. Biosimilar insulins: An unavoidable option in South-East Asia. Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):574-5. doi: 10.4103/2230-8210.183462. PubMed PMID: 27366730; PubMed Central PMCID: PMC4911853.
50. Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products; Board on Global Health; Institute of Medicine; Buckley GJ, Gostin LO, editors. Countering the Problem of Falsified and Substandard Drugs. Washington (DC): National Academies Press (US); 2013 May 20. 5, Weaknesses in the Drug Distribution Chain. Available from: https://www.ncbi.nlm.nih.gov/books/NBK202523/
51. Ezziane Z. Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges. Int J Health Policy Manag. 2014 Nov 6;3(7):365-70. doi: 10.15171/ijhpm.2014.118. eCollection 2014 Dec. Review. PubMed PMID: 25489593; PubMed Central PMCID: PMC4258887.